A Phase 3 interventional study of Eltrombopag and Antiviral therapy in Hepatitis C, sponsored by GlaxoSmithKline. Completed at 28 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hepatitis C by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C · GlaxoSmithKline.
Among the 21 studies in Hepatitis C by GlaxoSmithKline, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 12th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 21 studies in Hepatitis C by GlaxoSmithKline is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 53 across the 20 interventional studies, 1 across the 1 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Hepatitis C by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label eltrombopag with dose titrations to support adequate platelet counts.
Drug: Eltrombopag · Drug: Antiviral therapy
Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
Also known as: Promacta
Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.
Time frame: From the start of investigational product up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Number of Participants With Any AE and Any SAE in Part 2
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.
Time frame: From the date of initiation of antiviral therapy (Antiviral Baseline Visit [between Study Day 14 and Study Day 65]) to the completion of the follow-up period (up to Week 96/WD)
Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1
Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
Time frame: From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2
Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
Time frame: From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1
Blood samples were collected for the measurement of hematology parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
Time frame: From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2
Blood samples were collected for the measurement of hematology chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
Time frame: From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)
Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2
Visual acuity (VA) is defined as acuteness or clearness of vision.
Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2
LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.
Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Number of Participants With a logMAR Change >=0.15 During Parts 1 and 2
LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.
Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Platelet Counts at the Indicated Time Points
Blood samples were collected for the measurement of platelet count. For each participant, the duration of Part 1 treatment varies between 2 and 9 weeks.
Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Number of Particpants Who Initiated Antiviral Therapy
The number of participants who completed the Pre-antiviral Phase (Part 1) and proceeded to the Antiviral Phase (Part 2) are summarized.
Time frame: From the start of the investigational product up to 9 weeks (median of 21 days)
Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)
SVR is defined as non-detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of the planned treatment period (i.e., Week 48 or 72 for genotype 2/3 or Week 72 for non-genotype 2/3). RVR is defined as undetectable HCV RNA after 4 weeks of antiviral treatment. EVR is defined as clinically significant reduction in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. ETR is defined as undetectable HCV RNA at the end of antiviral treatment.
Time frame: From the start of investigational product in Part 2 up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
10\^9 cells (Giga) per liter=Gi/L; participants=par.; polyethylene glycol=Peg; interferon=INF.
| Milestone | Eltrombopag |
|---|---|
| Started | 27 |
| Completed | 26 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Eltrombopag |
|---|---|
| Started | 25 |
| Completed | 21 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 1 |
Blood samples were collected for the measurement of platelet count. For each participant, the duration of Part 1 treatment varies between 2 and 9 weeks.
| Gi/L | Eltrombopag |
|---|---|
| Screening, n=27 | 53.1 ± 12.90 |
| Part 1/Day 1, n=27 | 55.9 ± 18.69 |
| Part 1/Week 1, n=25 | 73.3 ± 29.27 |
| Part 1/Week 2, n=16 | 83.2 ± 27.90 |
| Part 1/Week 3, n=8 | 73.4 ± 26.53 |
| Part 1/Week 4, n=7 | 75.6 ± 19.95 |
| Part 1/Week 5, n=5 | 72.2 ± 18.29 |
| Part 1/Week 6, n=5 | 81.6 ± 14.45 |
| Part 1/Week 7, n=5 | 76.2 ± 19.88 |
| Part 1/Week 8, n=3 | 91.7 ± 22.81 |
| Part 2/Antiviral Baseline, n=25 | 132.9 ± 33.72 |
| Part 2/Week 1, n=25 | 106.7 ± 37.80 |
| Part 2/Week 2, n=25 | 93.2 ± 42.98 |
| Part 2/Week 4, n=23 | 80.5 ± 30.64 |
| Part 2/Week 8, n=21 | 80.3 ± 24.40 |
| Part 2/Week 12, n=20 | 83.1 ± 31.72 |
| Part 2/Week 16, n=16 | 85.8 ± 27.61 |
| Part 2/Week 20, n=14 | 75.3 ± 22.54 |
| Part 2/Week 24, n=11 | 78.6 ± 30.63 |
| Part 2/Week 28, n=9 | 90.3 ± 50.09 |
| Part 2/Week 32, n=7 | 86.1 ± 72.12 |
| Part 2/Week 36, n=6 | 76.8 ± 53.77 |
| Part 2/Week 40, n=5 | 55.8 ± 27.65 |
| Part 2/Week 44, n=5 | 54.4 ± 29.18 |
| Part 2/Week 48, n=2 | 68.0 ± 29.70 |
| Part 2/Week 52, n=1 | 49.0 ± NA |
| Part 2/Week 56, n=1 | 47.0 ± NA |
| Part 2/Week 60, n=1 | 43.0 ± NA |
| Part 2/Week 64, n=1 | 43.0 ± NA |
| Part 2/Week 68, n=1 | 44.0 ± NA |
| Post-treatment/4 Week Follow-up, n=23 | 77.8 ± 33.48 |
| Post-treatment/24 Week Follow-up, n=22 | 52.5 ± 17.91 |
| Investigational product discontinuation, n=26 | 91.3 ± 38.78 |
| Maximum value post-Baseline, n=26 | 145.5 ± 43.68 |
The number of participants who completed the Pre-antiviral Phase (Part 1) and proceeded to the Antiviral Phase (Part 2) are summarized.
| Participants | Eltrombopag |
|---|---|
| Yes | 25 |
| No | 2 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.
| Participants | Eltrombopag |
|---|---|
| Any SAE | 0 |
| Any AE | 9 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.
| Participants | Eltrombopag |
|---|---|
| Any SAE | 5 |
| Any AE | 25 |
Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
| Participants | Eltrombopag |
|---|---|
| Alanine amino transferase, Any Increase | 2 |
| Alanine amino transferase, Increase to Grade 1 | 1 |
| Alanine amino transferase, Increase to Grade 2 | 0 |
| Alanine amino transferase, Increase to Grade 3 | 1 |
| Alanine amino transferase, Increase to Grade 4 | 0 |
| Albumin, Any Increase | 1 |
| Albumin, Increase to Grade 1 | 1 |
| Albumin, Increase to Grade 2 | 0 |
| Albumin, Increase to Grade 3 | 0 |
| Albumin, Increase to Grade 4 | 0 |
| Alkaline phosphatase, Any Increase | 1 |
| Alkaline phosphatase, Increase to Grade 1 | 1 |
| Alkaline phosphatase, Increase to Grade 2 | 0 |
| Alkaline phosphatase, Increase to Grade 3 | 0 |
| Alkaline phosphatase, Increase to Grade 4 | 0 |
| Aspartate amino transferase, Any Increase | 2 |
| Aspartate amino transferase, Increase to Grade 1 | 2 |
| Aspartate amino transferase, Increase to Grade 2 | 0 |
| Aspartate amino transferase, Increase to Grade 3 | 0 |
| Aspartate amino transferase, Increase to Grade 4 | 0 |
| Creatinine, Any Increase | 0 |
| Creatinine, Increase to Grade 1 | 0 |
| Creatinine, Increase to Grade 2 | 0 |
| Creatinine, Increase to Grade 3 | 0 |
| Creatinine, Increase to Grade 4 | 0 |
| Total bilirubin, Any Increase | 10 |
| Total bilirubin, Increase to Grade 1 | 6 |
| Total bilirubin, Increase to Grade 2 | 4 |
| Total bilirubin, Increase to Grade 3 | 0 |
| Total bilirubin, Increase to Grade 4 | 0 |
| Uric acid, Any Increase | 3 |
| Uric acid, Increase to Grade 1 | 3 |
| Uric acid, Increase to Grade 2 | 0 |
| Uric acid, Increase to Grade 3 | 0 |
| Uric acid, Increase to Grade 4 | 0 |
Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
| Participants | Eltrombopag |
|---|---|
| Alanine amino transferase, Any Increase | 4 |
| Alanine amino transferase, Increase to Grade 1 | 3 |
| Alanine amino transferase, Increase to Grade 2 | 0 |
| Alanine amino transferase, Increase to Grade 3 | 1 |
| Alanine amino transferase, Increase to Grade 4 | 0 |
| Albumin, Any Increase | 9 |
| Albumin, Increase to Grade 1 | 4 |
| Albumin, Increase to Grade 2 | 5 |
| Albumin, Increase to Grade 3 | 0 |
| Albumin, Increase to Grade 4 | 0 |
| Alkaline phosphatase, Any Increase | 7 |
| Alkaline phosphatase, Increase to Grade 1 | 7 |
| Alkaline phosphatase, Increase to Grade 2 | 0 |
| Alkaline phosphatase, Increase to Grade 3 | 0 |
| Alkaline phosphatase, Increase to Grade 4 | 0 |
| Aspartate amino transferase, Any Increase | 9 |
| Aspartate amino transferase, Increase to Grade 1 | 1 |
| Aspartate amino transferase, Increase to Grade 2 | 8 |
| Aspartate amino transferase, Increase to Grade 3 | 0 |
| Aspartate amino transferase, Increase to Grade 4 | 0 |
| Creatinine, Any Increase | 1 |
| Creatinine, Increase to Grade 1 | 0 |
| Creatinine, Increase to Grade 2 | 0 |
| Creatinine, Increase to Grade 3 | 1 |
| Creatinine, Increase to Grade 4 | 0 |
| Total bilirubin, Any Increase | 16 |
| Total bilirubin, Increase to Grade 1 | 1 |
| Total bilirubin, Increase to Grade 2 | 5 |
| Total bilirubin, Increase to Grade 3 | 10 |
| Total bilirubin, Increase to Grade 4 | 0 |
| Uric acid, Any Increase | 5 |
| Uric acid, Increase to Grade 1 | 4 |
| Uric acid, Increase to Grade 2 | 1 |
| Uric acid, Increase to Grade 3 | 0 |
| Uric acid, Increase to Grade 4 | 0 |
Blood samples were collected for the measurement of hematology parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
| Participants | Eltrombopag |
|---|---|
| Hemoglobin, Any Increase | 2 |
| Hemoglobin, Increase to Grade 1 | 2 |
| Hemoglobin, Increase to Grade 2 | 0 |
| Hemoglobin, Increase to Grade 3 | 0 |
| Hemoglobin, Increase to Grade 4 | 0 |
| Lymphocytes, Any Increase | 3 |
| Lymphocytes, Increase to Grade 1 | 1 |
| Lymphocytes, Increase to Grade 2 | 1 |
| Lymphocytes, Increase to Grade 3 | 1 |
| Lymphocytes, Increase to Grade 4 | 0 |
| Total neutrophils, Any Increase | 3 |
| Total neutrophils, Increase to Grade 1 | 3 |
| Total neutrophils, Increase to Grade 2 | 0 |
| Total neutrophils, Increase to Grade 3 | 0 |
| Total neutrophils, Increase to Grade 4 | 0 |
| White Blood cell count, Any Increase | 2 |
| White Blood cell count, Increase to Grade 1 | 0 |
| White Blood cell count, Increase to Grade 2 | 2 |
| White Blood cell count, Increase to Grade 3 | 0 |
| White Blood cell count, Increase to Grade 4 | 0 |
Blood samples were collected for the measurement of hematology chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.
| Participants | Eltrombopag |
|---|---|
| Hemoglobin, Any Increase | 12 |
| Hemoglobin, Increase to Grade 1 | 1 |
| Hemoglobin, Increase to Grade 2 | 5 |
| Hemoglobin, Increase to Grade 3 | 5 |
| Hemoglobin, Increase to Grade 4 | 1 |
| Lymphocytes, Any Increase | 15 |
| Lymphocytes, Increase to Grade 1 | 1 |
| Lymphocytes, Increase to Grade 2 | 3 |
| Lymphocytes, Increase to Grade 3 | 3 |
| Lymphocytes, Increase to Grade 4 | 8 |
| Total neutrophils, Any Increase | 23 |
| Total neutrophils, Increase to Grade 1 | 4 |
| Total neutrophils, Increase to Grade 2 | 10 |
| Total neutrophils, Increase to Grade 3 | 8 |
| Total neutrophils, Increase to Grade 4 | 1 |
| White Blood Cell count, Any Increase | 20 |
| White Blood Cell count, Increase to Grade 1 | 5 |
| White Blood Cell count, Increase to Grade 2 | 7 |
| White Blood Cell count, Increase to Grade 3 | 7 |
| White Blood Cell count, Increase to Grade 4 | 1 |
Visual acuity (VA) is defined as acuteness or clearness of vision.
| Participants | Eltrombopag |
|---|---|
| Decrease in Visual Acuity, Yes | 10 |
| Decrease in Visual Acuity, No | 15 |
| Decrease in Visual Acuity, Missing or Unknown | 2 |
LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.
| Participants | Eltrombopag |
|---|---|
| logMAR Changes, <0.10 (No Change or Improvement) | 15 |
| logMAR Changes, >=0.10 to <0.20 (Loss of 1 Line) | 6 |
| logMAR Changes, >=0.20 to <0.30 (Loss of 2 Lines) | 3 |
| logMAR Changes, >=0.30 (Loss of 3 Lines or more) | 1 |
| logMAR Changes, Missing or Unknown | 2 |
LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.
| Participants | Eltrombopag |
|---|---|
| logMAR change, Yes | 4 |
| logMAR change, No | 21 |
| logMAR change, Missing or Unknown | 2 |
SVR is defined as non-detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of the planned treatment period (i.e., Week 48 or 72 for genotype 2/3 or Week 72 for non-genotype 2/3). RVR is defined as undetectable HCV RNA after 4 weeks of antiviral treatment. EVR is defined as clinically significant reduction in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. ETR is defined as undetectable HCV RNA at the end of antiviral treatment.
| Participants | Eltrombopag |
|---|---|
| SVR, Yes, n=17 | 4 |
| SVR, No, n=17 | 13 |
| RVR, Yes, n=12 | 3 |
| RVR, No, n=12 | 9 |
| EVR, Yes, n=15 | 15 |
| EVR, No, n=15 | 0 |
| ETR, Yes, n=21 | 9 |
| ETR, No, n=21 | 12 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of the 24-week follow up period (up to Week 96/WD).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag (Part 1) | — | 0/27 (0%) | 9/27 (33.3%) |
| Eltrombopag (Part 2) | — | 5/25 (20%) | 25/25 (100%) |
| Event | Eltrombopag (Part 1) | Eltrombopag (Part 2) |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 0/27 | 1/25 |
| Myoclonic epilepsyNervous system disorders | 0/27 | 1/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/27 | 1/25 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/27 | 1/25 |
| CellulitisInfections and infestations | 0/27 | 1/25 |
| Metabolic disorderMetabolism and nutrition disorders | 0/27 | 1/25 |
| Event | Eltrombopag (Part 1) | Eltrombopag (Part 2) |
|---|---|---|
| PyrexiaGeneral disorders | 0/27 | 9/25 |
| NauseaGastrointestinal disorders | 2/27 | 7/25 |
| HeadacheNervous system disorders | 2/27 | 7/25 |
| LeukopeniaBlood and lymphatic system disorders | 0/27 | 7/25 |
| FatigueGeneral disorders | 0/27 | 7/25 |
| AnaemiaBlood and lymphatic system disorders | 1/27 | 6/25 |
| AstheniaGeneral disorders | 1/27 | 5/25 |
| Influenza like illnessGeneral disorders | 0/27 | 5/25 |
| DiarrhoeaGastrointestinal disorders | 0/27 | 4/25 |
| VomitingGastrointestinal disorders | 0/27 | 4/25 |
| Age Continuous(Years) | Eltrombopag |
|---|---|
| Mean | 51.3 ± 7.70 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 7 |
| Male | 20 |
| Race/Ethnicity, Customized(participants) | Eltrombopag |
|---|---|
| Central/South Asian Heritage | 2 |
| White | 25 |
The record gives a start of Sep 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag